Company News
Glenmark Advances Phase 3 Ovarian Cancer Trial
Glenmark Specialty S.A initiates multi-country Phase 3 trial for Trastuzumab rezetecan in platinum-resistant ovarian cancer following DCGI approval.
India is first market to enroll patients, with Aust
